{"id":56906,"date":"2026-02-11T22:22:29","date_gmt":"2026-02-11T14:22:29","guid":{"rendered":"https:\/\/flcube.com\/?p=56906"},"modified":"2026-04-21T20:47:03","modified_gmt":"2026-04-21T12:47:03","slug":"hengrui-pharmas-trastuzumab-rezetecan-filing-accepted-for-her2-colorectal-cancer-indication","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56906","title":{"rendered":"Hengrui Pharma\u2019s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication"},"content":{"rendered":"\n<p><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<strong><a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA:\u202f600276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG:\u202f1276<\/a><\/strong>) announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has <strong>accepted for review<\/strong> a <strong>new indication filing<\/strong> for <strong>trastuzumab rezetecan<\/strong>, its <strong>in-house developed HER2-targeted antibody-drug conjugate (ADC)<\/strong>. The submission seeks approval for <strong>HER2-positive colorectal cancer<\/strong> in patients who have <strong>failed prior oxaliplatin, fluorouracil, and irinotecan therapy<\/strong>, based on <strong>positive Phase III data<\/strong> demonstrating <strong>significant progression-free survival (PFS) improvement<\/strong> and <strong>disease progression risk reduction<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Jiangsu Hengrui Pharmaceuticals (SHA:\u202f600276, HKG:\u202f1276)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>Trastuzumab rezetecan \u2013 HER2-targeted ADC<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>HER2-positive colorectal cancer (post-oxaliplatin\/fluorouracil\/irinotecan failure)<\/td><\/tr><tr><td><strong>Filing Basis<\/strong><\/td><td>Phase III clinical trial results<\/td><\/tr><tr><td><strong>Prior Approval<\/strong><\/td><td>HER2-mutant NSCLC (May\u202f2025) \u2013 <strong>first approved indication<\/strong><\/td><\/tr><tr><td><strong>Pending Decision<\/strong><\/td><td>HER2-positive breast cancer (post-anti-HER2 therapy)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-summary\">Clinical Evidence Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Trastuzumab Rezetecan vs. Standard Therapy<\/th><th>Clinical Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Progression-Free Survival (PFS)<\/strong><\/td><td><strong>Significantly prolonged<\/strong><\/td><td>Primary endpoint met; tumor growth delay<\/td><\/tr><tr><td><strong>Disease Progression or Death Risk<\/strong><\/td><td><strong>Significantly reduced<\/strong><\/td><td>Meaningful clinical benefit in refractory population<\/td><\/tr><tr><td><strong>Overall Survival (OS)<\/strong><\/td><td><strong>Trend toward benefit observed<\/strong><\/td><td>Mature data anticipated to confirm survival advantage<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Population:<\/strong> HER2-positive advanced colorectal cancer with <strong>prior failure on standard chemotherapy backbone<\/strong> (oxaliplatin, fluoropyrimidine, irinotecan) \u2013 <strong>high-unmet-need, heavily pretreated setting<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-approved-amp-pending-indications\">Approved &amp; Pending Indications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Status<\/th><th>Approval Date\/Expected<\/th><\/tr><\/thead><tbody><tr><td><strong>HER2-mutant NSCLC<\/strong> (unresectable locally advanced\/metastatic; \u22651 prior systemic therapy)<\/td><td><strong>Approved<\/strong><\/td><td><strong>May\u202f2025<\/strong><\/td><\/tr><tr><td><strong>HER2-positive colorectal cancer<\/strong> (post-chemotherapy failure)<\/td><td><strong>Under NMPA review<\/strong><\/td><td>2026-2027<\/td><\/tr><tr><td><strong>HER2-positive breast cancer<\/strong> (post-anti-HER2 therapy)<\/td><td><strong>Awaiting regulatory decision<\/strong><\/td><td>2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning-amp-market-context\">Strategic Positioning &amp; Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Strategic Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>HER2+ Colorectal Cancer Prevalence<\/strong><\/td><td><strong>~3-5% of metastatic colorectal cancers<\/strong> HER2-amplified; <strong>no approved HER2-targeted therapies<\/strong> in China for this indication \u2013 <strong>first-mover opportunity<\/strong><\/td><\/tr><tr><td><strong>ADC Competitive Landscape<\/strong><\/td><td><strong>Trastuzumab deruxtecan (Enhertu, AstraZeneca\/Daiichi)<\/strong> approved for HER2+ colorectal cancer in US\/Japan; Hengrui&#8217;s <strong>domestic manufacturing and pricing advantage<\/strong> for China market<\/td><\/tr><tr><td><strong>Hengrui Oncology Portfolio<\/strong><\/td><td>Trastuzumab rezetecan anchors <strong>HER2 ADC franchise<\/strong>; complements <strong>SHR-A1811 (HER2 ADC)<\/strong> and <strong>pyrotinib (HER2 TKI)<\/strong> in breast cancer<\/td><\/tr><tr><td><strong>NRDL Pathway<\/strong><\/td><td>Sequential indication approvals build <strong>reimbursement negotiation leverage<\/strong>; colorectal cancer expands addressable market beyond NSCLC<\/td><\/tr><tr><td><strong>Global Potential<\/strong><\/td><td>NMPA approval supports <strong>ex-China partnership discussions<\/strong>; HER2+ colorectal cancer represents <strong>orphan indication with premium pricing<\/strong> in US\/EU<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding trastuzumab rezetecan NMPA approval timelines for HER2+ colorectal cancer, commercial market penetration, and competitive positioning vs. trastuzumab deruxtecan. Actual results may differ due to regulatory review delays, pricing pressure from national procurement programs, and biomarker testing adoption in Chinese oncology practice.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2026021001086_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026021001086_c.\"><\/object><a id=\"wp-block-file--media-3d091a5e-562a-4402-902e-92d909a7fda9\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2026021001086_c.pdf\">2026021001086_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2026021001086_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-3d091a5e-562a-4402-902e-92d909a7fda9\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA:\u202f600276, HKG:\u202f1276) announced that the National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,16,2586,4228,38,852],"class_list":["post-56906","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-cancer","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-market-approval-filings","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui Pharma\u2019s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA:\u202f600276, HKG:\u202f1276) announced that the National Medical Products Administration (NMPA) has accepted for review a new indication filing for trastuzumab rezetecan, its in-house developed HER2-targeted antibody-drug conjugate (ADC). The submission seeks approval for HER2-positive colorectal cancer in patients who have failed prior oxaliplatin, fluorouracil, and irinotecan therapy, based on positive Phase III data demonstrating significant progression-free survival (PFS) improvement and disease progression risk reduction.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56906\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui Pharma\u2019s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA:\u202f600276, HKG:\u202f1276) announced that the National Medical Products Administration (NMPA) has accepted for review a new indication filing for trastuzumab rezetecan, its in-house developed HER2-targeted antibody-drug conjugate (ADC). The submission seeks approval for HER2-positive colorectal cancer in patients who have failed prior oxaliplatin, fluorouracil, and irinotecan therapy, based on positive Phase III data demonstrating significant progression-free survival (PFS) improvement and disease progression risk reduction.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56906\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-11T14:22:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-21T12:47:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56906#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56906\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui Pharma\u2019s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication\",\"datePublished\":\"2026-02-11T14:22:29+00:00\",\"dateModified\":\"2026-04-21T12:47:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56906\"},\"wordCount\":416,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Cancer\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"Market approval filings\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56906#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56906\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56906\",\"name\":\"Hengrui Pharma\u2019s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-11T14:22:29+00:00\",\"dateModified\":\"2026-04-21T12:47:03+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA:\u202f600276, HKG:\u202f1276) announced that the National Medical Products Administration (NMPA) has accepted for review a new indication filing for trastuzumab rezetecan, its in-house developed HER2-targeted antibody-drug conjugate (ADC). The submission seeks approval for HER2-positive colorectal cancer in patients who have failed prior oxaliplatin, fluorouracil, and irinotecan therapy, based on positive Phase III data demonstrating significant progression-free survival (PFS) improvement and disease progression risk reduction.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56906#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56906\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56906#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui Pharma\u2019s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui Pharma\u2019s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA:\u202f600276, HKG:\u202f1276) announced that the National Medical Products Administration (NMPA) has accepted for review a new indication filing for trastuzumab rezetecan, its in-house developed HER2-targeted antibody-drug conjugate (ADC). The submission seeks approval for HER2-positive colorectal cancer in patients who have failed prior oxaliplatin, fluorouracil, and irinotecan therapy, based on positive Phase III data demonstrating significant progression-free survival (PFS) improvement and disease progression risk reduction.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56906","og_locale":"en_US","og_type":"article","og_title":"Hengrui Pharma\u2019s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication","og_description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA:\u202f600276, HKG:\u202f1276) announced that the National Medical Products Administration (NMPA) has accepted for review a new indication filing for trastuzumab rezetecan, its in-house developed HER2-targeted antibody-drug conjugate (ADC). The submission seeks approval for HER2-positive colorectal cancer in patients who have failed prior oxaliplatin, fluorouracil, and irinotecan therapy, based on positive Phase III data demonstrating significant progression-free survival (PFS) improvement and disease progression risk reduction.","og_url":"https:\/\/flcube.com\/?p=56906","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-11T14:22:29+00:00","article_modified_time":"2026-04-21T12:47:03+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56906#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56906"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui Pharma\u2019s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication","datePublished":"2026-02-11T14:22:29+00:00","dateModified":"2026-04-21T12:47:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56906"},"wordCount":416,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Cancer","Hengrui Pharmaceuticals","HKG: 1276","Market approval filings","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56906#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56906","url":"https:\/\/flcube.com\/?p=56906","name":"Hengrui Pharma\u2019s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-11T14:22:29+00:00","dateModified":"2026-04-21T12:47:03+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA:\u202f600276, HKG:\u202f1276) announced that the National Medical Products Administration (NMPA) has accepted for review a new indication filing for trastuzumab rezetecan, its in-house developed HER2-targeted antibody-drug conjugate (ADC). The submission seeks approval for HER2-positive colorectal cancer in patients who have failed prior oxaliplatin, fluorouracil, and irinotecan therapy, based on positive Phase III data demonstrating significant progression-free survival (PFS) improvement and disease progression risk reduction.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56906#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56906"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56906#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui Pharma\u2019s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56906","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56906"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56906\/revisions"}],"predecessor-version":[{"id":56909,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56906\/revisions\/56909"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56906"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56906"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}